InnoPharma LABORATORIO	**TECHNICAL INFORMATION** **VETERINARY PRODUCTS**
	CORTIDEX **Injectable Solution** **2 mg / mL**

Cortidex

Registration No. Q-0666-091

FÓRMULA:
Each mL contains:

Dexamethasone base.....2 mg
(As 21 Dexamethasone phosphate)
Vehicle c.b.p.....1 mL

Cortidex® It is a potent anti-inflammatory indicated in acute, sub-acute and chronic inflammatory processes. As part of complementary treatments for mastitis, it helps to suppress the metabolic and circulatory effects of endotoxins, treatment of ketosis, systemic conditions such as polyarthritis and tendinitis.

Synthetic glucocorticoid with potency 20–30 times that of hydrocortisone and 4–5 times that of prednisone. 9-fluoro-11β,17,21-trihidroxi-16a-metilpregna-1,4-dieno-3,20-diona.



PHARMACODYNAMICS AND PHARMACOKINETICS
Maximum plasma concentrations are obtained after 1–2 hours. The duration of action of injected dexamethasone depends on the mode of injection (intravenous, intramuscular or intra-articular) and on the irrigation of the injection site.
After administration on the skin, the degree of absorption of the product depends on the integrity of the skin. It increases in injured areas and is particularly intense where the stratum corneum is thinner. After ophthalmic administration of dexamethasone, only minimal systemic absorption occurs.

In the systemic circulation, dexamethasone binds weakly to plasma proteins, the portion not bound to proteins being active. The drug is rapidly distributed in the kidneys, intestines, liver, skin and muscles. Corticosteroids cross the placental barrier and are excreted in milk. Dexamethasone is metabolized in the liver giving rise to inactive products which are eliminated in the urine. The elimination half-life is 1.8 to 3.5 hours and the biological half-life is 36 to 54 hours.

The sodium phosphate salt of dexamethasone is one of the most soluble glucocorticoid compounds, so that injectable preparations in aqueous vehicle allow immediate bioavailability intravenously and slightly slower when administered intramuscularly or locally intratissularly. Dexamethasone, like other glucocorticoids, acts at the cellular level by binding to intracellular cytoplasmic steroid receptors and exerts its anti-inflammatory effect at the level of all tissues, preventing tissue response and the cascade reaction of the inflammatory process by blocking the production of prostaglandins and leukotrienes. Its concentration in tissues stabilizes lysosomal enzymes and acts by maintaining capillary integrity and preventing the migration of immune complexes through basement membranes. Its effect on the various cellular components of the inflammatory process is exerted by altering the function of monocytes, macrophages and T-lymphocytes.
During the antigen-antibody reaction, it prevents macrophage and mast cell reaction to migration and granulation factors of the latter; it also inhibits phagocytosis and antigen digestion.
It inhibits the production of interleukins 1 and 2 and the T-lymphocyte proliferation mediator that normally occurs upon mitogen exposure. These effects are considered the basis of its anti-inflammatory and immune response blocking effect.

The inhibition of the processes described above by the effect of glucocorticoids at the cellular level reduces the clinical manifestations of inflammatory and some immunological pathological processes.
The administration at therapeutic doses of oral or injectable dexamethasone in the early stages of these processes, determines a regressive effect of the cellular process and in some cases can avoid the late fibrogenesis (scarring) phase of the inflammatory process.

PRECAUTIONS AND RESTRICTIONS OF USE.
Do not use this product 35 days before slaughter of animals intended for human consumption.
Do not leave within reach of children and domestic animals.
Do not use in pregnant females.
Do not apply in cases of renal and/or hepatic insufficiency, congestive heart failure, osteoporosis, bone fractures, Diabetes, ocular degenerative diseases or corneal ulcer, Cushing's syndrome and animals subjected to immunological treatment.
Do not use in females producing milk for human consumption.
Do not use in equines destined for human consumption.

DRUG-DRUG INTERACTIONS:
Do not administer in conjunction with antidiabetics, barbiturates, diuretics, potassium depressants, indomethacin, salicylates and antihistamines.

TOXICITY AND SAFETY:
Symptoms include: anxiety, depression, mental confusion, gastrointestinal spasms or bleeding, hyperglycemia, high blood pressure, and edema. Risk of cyclosporine toxicity if high doses of corticosteroids are used.

There is no specific antidote in case of overdose; treatment is symptomatic and supportive.
In case of overdose, behavioral alterations, nervousness, insomnia, mood changes, etc. are likely to occur.

DOSAGE AND ROUTE OF ADMINISTRATION:
0.02 to 2 mg/kg body weight, depending on the specific use of each species.

Bovines meat producers: 2.5 to 10 mL
Equines: 2.5 to 5 mL
Porcines: 1 to 5 mL
Ovines and Caprines: 1 to 2 mL
Canines: 0.4 to 0.5 mL as anti-inflammatory (0.05 mL/kg or 0.5 mL/10 kg)

Suggested doses in

Bovines
As anti-inflammatory and anti-allergic: 5 to 40 mg per animal (2.5 - 20 mL per animal) single dose.
Anaphylactic shock: 1 to 4 mg/kg (0.5 to 2 mL/kg) every 4 hours IV.
Part of the treatment of ketosis: administer 0.02 - 0.04 mg/kg/IM (1 - 2 mL/100 kg) or 5 - 20 mg total as a single IM dose (2.5 - 10 mL).

Equines
Anti-inflammatory and anti-allergic: 2.5 to 20 mg (1.25 - 10 mL) as a single dose per animal once daily.

Canines
As anti-inflammatory: 0.1 mg/kg (0.05 mL/kg or 0.5 mL/10 kg) every 24 hours IM, SC or IV.
Acute allergic reactions: Dose of 1 - 4 mg/kg (0.5 - 2 mL/ kg) IV. single dose, or can be repeated with an interval of 24 hours.
In shock, 2 - 8 mg/kg (1 - 4 mL/kg) IV as a single dose.
Autoimmune hemolytic anemia 0.1 - 0.6 mg/kg (0.05 - 0.3 mL/kg or 0.5 - 3 mL/10 kg) IV single dose.
Can also be used in Addison's crisis, or as a diagnosis of hyperadrenocorticism, as well as immunosuppressant.

PRESENTATION:
Box with bottle with 10, 20, 50, 100 mL.

STORAGE RECOMMENDATIONS:
Store in a cool, dry place.
Protect from light.

ITS SALE REQUIRES MEDICAL ADVICE.

Consult your Veterinarian Doctor.

InnoPharma LABORATORIO	**TECHNICAL INFORMATION** **VETERINARY PRODUCTS**
	CORTIDEX **Injectable Solution** **2 mg / mL**

PRODUCT FOR EXCLUSIVE USE IN VETERINARY MEDICINE.
GLP

MADE IN MEXICO BY:
INNOPHARMA, S. DE R.L. DE C.V.
Av. San Pablo No. 79-C,
Col. Santa Barbara, Azcapotzalco,
Mexico City, CP. 02230
Tel: 55 5985 3020 Ext.512-522
ia_ventas@loeffler.com.mx
www.loefflervet.com.mx